Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. - Following these disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages affected investors to seek additional information and potential legal options [2][5]. - The law firm operates on a contingency fee basis, meaning shareholders are not responsible for court costs or litigation expenses [5]. Company Overview - Ardent Health, Inc. provides healthcare services in mid-sized urban communities across the U.S., operating a network of hospitals, ambulatory facilities, and physician practices [3].

ARDT INVESTORS: BFA Law Reminds Ardent Health, Inc. Investors with Losses to Contact the Firm About its Ongoing Securities InvestigationNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential violations of the federal securities laws. If you invested in Ardent, you are encouraged to obtain addition ...

ARDT INVESTIGATION: Ardent Health, Inc. Investors that Suffered Losses are Notified to Contact BFA Law about the Ongoing Securities InvestigationNovember 19, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 19, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential violations of the federal securities laws. If you invested in Ardent, you are encouraged to obtain ...

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Live Oak Bancshares, Inc. (“Live Oak” or “the Company”) (NYSE: LOB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Live Oak disclosed in a SEC filing on November 12, 2025, that “"the C ...

Accessibility StatementSkip Navigation WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and ...

Core Insights - Stride, Inc. is under investigation for possible violations of federal securities laws following disappointing enrollment numbers and guidance despite beating earnings expectations [1][2] - The company's stock price experienced a significant drop of $68.51, opening at $85.02 per share after the earnings report [3] Financial Performance - Stride reported its first quarter fiscal 2026 earnings on October 28, 2025, which exceeded market expectations [2] - However, enrollment numbers and forward-looking guidance were significantly below expectations, indicating potential operational challenges [2] Operational Challenges - Stride has invested in upgrading its learning and technology platforms, but the implementations faced difficulties, leading to higher withdrawal rates and lower conversion rates than anticipated [2]

Core Insights - Zimmer Biomet Holdings, Inc. reported third-quarter 2025 net sales of $2 billion, which fell short of consensus estimates of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness was noted in international markets and non-core businesses, with specific challenges in the Middle East and Eastern Europe impacting results [2] - Following the earnings announcement, Zimmer Biomet's stock price dropped over 15% on November 5, 2025 [3] Financial Performance - Net sales for Q3 2025 were reported at $2 billion, missing the expected $2.01 billion [2] - The revised outlook for full-year organic revenue growth is now projected at 3.5% to 4% [2] Market Challenges - The company faced challenges in international markets and non-core businesses, leading to a decline in performance [2] - There were specific issues with distributors and order cancellations in the Middle East and Eastern Europe [2] - Analysts expressed concerns regarding lower-than-expected growth in U.S. knee and hip replacement sales, indicating potential operational control issues [2]

Company Overview - Simulations Plus, Inc. provides software and consulting services to support drug discovery and development in the pharmaceutical industry [3]. Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Simulations Plus, stemming from allegations of providing misleading business information to investors [1]. - On April 15, 2025, Simulations Plus hired Grant Thornton as its auditor. Following weak preliminary Q3 results reported in June, the company's stock dropped over 24% to close at $20.05 per share [4]. - On July 14, 2025, Simulations Plus reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, despite the auditor's objections regarding unresolved reporting and internal control issues. This led to a further stock decline of 25.76%, closing at $12.97 per share [4].

Core Insights - Faruqi & Faruqi, LLP is investigating potential securities law violations at Avantor, Inc. following disappointing financial results [2][3] - Avantor reported a net loss of $712 million for Q3 2025, primarily due to a non-cash goodwill impairment charge of $785 million, alongside a -5% organic revenue growth [3][4] - The company's stock price dropped over 23%, falling from $15.08 to $11.58 per share after the announcement of the financial results [4] Company Performance - Avantor's Q3 2025 results included a net loss of $712 million, attributed mainly to a goodwill impairment charge [3] - The company experienced a -5% organic revenue growth, which was below the guidance provided earlier in August [3] Market Reaction - Following the announcement of the financial results, Avantor's stock price fell by $3.50 per share, representing a decline of more than 23% [4]

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avantor, Inc. (NYSE: AVTR). Shareholders who purchased shares of AVTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avantor-inc-loss-submission-form/?id=175418&from=3  CLASS PERIOD: March 5, 2024 to Oct ...